(Q34481465)

2 August 2017

1 reference

title

An analysis of the attrition of drug candidates from four major pharmaceutical companies (English)

1 reference

2 August 2017

3

Andrew R Leach

1 reference

2 August 2017

Michael J Waring

1

1 reference

2 August 2017

John Arrowsmith

2

1 reference

2 August 2017

Paul D Leeson

4

1 reference

2 August 2017

Sam Mandrell

5

1 reference

2 August 2017

Robert M Owen

6

1 reference

2 August 2017

Garry Pairaudeau

7

1 reference

2 August 2017

William D Pennie

8

1 reference

2 August 2017

Stephen D Pickett

9

1 reference

2 August 2017

Jibo Wang

10

1 reference

2 August 2017

Owen Wallace

11

1 reference

2 August 2017

Alex Weir

12

1 reference

2 August 2017

19 June 2015

1 reference

Nature Reviews Drug Discovery

2 August 2017

1 reference

2 August 2017

14

1 reference

2 August 2017

475-486

1 reference

2 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4609

2 August 2017

0 references

cites work

Clinical development success rates for investigational drugs

1 reference

Getting pharmaceutical R&D back on target

31 March 2020

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

The influence of drug-like concepts on decision-making in medicinal chemistry

31 March 2020

1 reference

Generation of a set of simple, interpretable ADMET rules of thumb

31 March 2020

1 reference

Physiochemical drug properties associated with in vivo toxicological outcomes

31 March 2020

1 reference

Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds

31 March 2020

1 reference

Probing the links between in vitro potency, ADMET and physicochemical parameters.

31 March 2020

1 reference

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules

31 March 2020

1 reference

Inflation of correlation in the pursuit of drug-likeness

31 March 2020

1 reference

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

31 March 2020

1 reference

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

31 March 2020

1 reference

Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes

31 March 2020

1 reference

Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies

31 March 2020

1 reference

The influence of the 'organizational factor' on compound quality in drug discovery

31 March 2020

1 reference

Escape from flatland: increasing saturation as an approach to improving clinical success.

31 March 2020

1 reference

The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds

31 March 2020

1 reference

Dependence of molecular properties on proteomic family for marketed oral drugs

31 March 2020

1 reference

Accurate In Silico log PPredictions: One Can't Embrace the Unembraceable

31 March 2020

1 reference

Lipophilicity in drug discovery

31 March 2020

1 reference

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

31 March 2020

1 reference

Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability

31 March 2020

1 reference

A quantitative assessment of hERG liability as a function of lipophilicity

31 March 2020

1 reference

Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD4609

1 reference

2 August 2017

1 reference